Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

February 22, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

January 30, 2020

Conditions
Lung NeoplasmsLung Cancer, Nonsmall CellAdenocarcinoma of LungSquamous Cell Lung Cancer
Trial Locations (14)

510120

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

Unknown

First Hospital of Jilin University, Changchun

Sir Run Run Shaw Hospital, Zhejiang University School of medicine, Hangzhou

The First Hospital of Zhejiang Province, Hangzhou

Anhui Provincial Hospital, Hefei

Jiangsu Jiangyin People's Hospital, Jiangyin

The Second Affiliated Hospital of Nanchang University, Nanchang

Ningbo No.2 Hospital, Ningbo

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

Shanghai Changzheng Hospital, Shanghai

Shanghai Chest Hospital, Shanghai

Shanghai East Hospital, Shanghai

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

Affiliated Hospital, Jiangnan University, Wuxi

All Listed Sponsors
collaborator

Shanghai Chest Hospital

OTHER

lead

Geneplus-Beijing Co. Ltd.

INDUSTRY

NCT03059641 - Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China | Biotech Hunter | Biotech Hunter